Purpura Thrombocytopenic Idiopathic
📧 Sign up to get email alerts when something new happens for Purpura Thrombocytopenic Idiopathic.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-06-24EMA Authorised: Privigen (human normal immunoglobulin (IVIg)) — CSL Behring GmbH
Authorised status for Privigen (human normal immunoglobulin IVIg) by CSL Behring GmbH in the EMA; therapeutic areas include various immunolo…
-
EMA approval · 2024-01-11EMA Authorised: Flebogamma DIF (previously Flebogammadif) (human normal immunoglobulin) — Instituto Grifols S.A.
EMA authorises Flebogamma DIF (human normal immunoglobulin) for multiple immunological indications including mucocutaneous lymph node syndro…
-
EMA approval · 2022-06-27EMA Authorised: Kiovig (human normal immunoglobulin (IVIg)) — Takeda Manufacturing Austria AG
Kiovig (human normal immunoglobulin IVIg) has been authorised by EMA for multiple indications including immune thrombocytopenic purpura, bon…
-
CLINICAL_TRIALS trial_result · 2018-08-15Clinical Trial Update: Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP [Phase 3]
Phase 3 trial comparing decitabine plus dexamethasone versus dexamethasone alone for management of immune thrombocytopenia, status not repor…
-
CLINICAL_TRIALS trial_result · 2018-02-23Clinical Trial Update: Rituximab Combining Bortezomib Versus Rituximab in Management of ITP [Phase 3]
A Phase 3 trial evaluating rituximab combined with bortezomib versus rituximab alone for immune thrombocytopenia.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2011-12-01Clinical Trial Update: Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP) [Phase 3]
Phase 3 trial evaluating eltrombopag for chronic idiopathic thrombocytopenic purpura (ITP) completed with results posted in 2011.